ClinicalTrials.Veeva

Menu

Bowel Dysfunction After Low Rectal Resection. An Pilot Study Using Psyllium Husk In Rectal Cancer Patients.

S

Sykehuset Telemark

Status

Active, not recruiting

Conditions

Quality of Life (QOL)
Low Anterior Resection Syndrome

Treatments

Dietary Supplement: Psyllium husk

Study type

Interventional

Funder types

Other

Identifiers

NCT06724198
2024/732141(REK)

Details and patient eligibility

About

Rectal cancer constitutes 1/3 of more than 4500 annually diagnosed cases of colorectal (CRC) in Norway. With the advances in radiochemotherapy, and surgical techniques, the long-term survival rate is increasing after surgery regardless of the rising incidences, with a 73% 5-year survival rate in Norway (89% for stage I-III cancer). Low anterior resection (LAR) is the most commonly performed surgical procedure with curative intent with over 500 procedures per year in Norway alone. 80 % of patients subjected to LAR suffer from the LAR syndrome (LARS) which includes grades of bowel incontinence, urgency and tenesmus contributing to reduced quality of life (QoL). Suggested means of management have been advocated without preceding randomized trials. Psyllium husk has been suggested as a nutritional supplement for symptom reduction in patients suffering from LARS, but data is limited and no larger, randomized studies regarding its effect on patients with low anterior resection syndrome have been conducted. In this pilot study preceeding a placebo-controlled RCT, the investigators aim to improve documentation of a proposed management strategy. The investigators anticipate that a reduction in intestinal symptomburden will increase QoL for this large patientgroup.

Enrollment

20 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Operated with low rectal resection for rectal cancer
  • LARS score >20 at 12 months or more after surgery
  • Written consent

Exclusion criteria

  • Various conditions rendering the patient unable to answer questionnaire
  • LARS score 0-20
  • Contraindications to Psyllium husk (hypersensitivity, intestinal obstruction, reduced esophageal function, rare congenital medical conditions such as sucrase-isomaltase deficiency, fructose intolerance and glucose-galactose malabsorbtion)

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Intervention group
Experimental group
Description:
Participants will recieve Psyllium husk twice daily for 8 weeks
Treatment:
Dietary Supplement: Psyllium husk

Trial contacts and locations

1

Loading...

Central trial contact

Silje S Holte; Johannes K Schultz

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems